BIFIDO Co., Ltd.
Financials
Valuation Metrics
BIFIDO Co., Ltd.'s Market Cap is ₩220B. At end of 2025 it was ₩251B. Ranked #2278 of 2,421 in KR market (top 94%), #1512 of 1,640 on KOSDAQ (top 92%), #51 of 57 in Household & Personal Products (top 89%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 21.96B KRW | KR#2,278/2,421 Sec#51/57 |
| Revenue | 14.63B KRW | KR#2,218/2,421 Sec#50/57 |
| Net Income | 1.85B KRW | KR#1,424/2,421 Sec#34/57 |
| Total Assets | 64.21B KRW | KR#2,066/2,421 Sec#46/57 |
| Net Assets | 48.94B KRW | KR#1,920/2,421 Sec#42/57 |
| Employees | 101 | KR#1,628/2,421 Sec#34/57 |
| Value | ||
| P/E | 11.88x | KR#918/2,421 Sec#22/57 |
| P/B | 0.45x | KR#686/2,421 Sec#13/57 |
| P/S | 1.50x | KR#1,639/2,421 Sec#41/57 |
| FCF Yield | -14.77% | KR—/2,421 Sec—/57 |
| Profitability | ||
| ROE | 3.78% | KR#1,245/2,421 Sec#30/57 |
| ROA | 2.88% | KR#1,058/2,421 Sec#30/57 |
| Op. Margin | -6.99% | KR#1,920/2,421 Sec#45/57 |
| Revenue Growth | -15.44% | KR#2,050/2,421 Sec#51/57 |
| Financial Health | ||
| Debt Ratio | 31.22% | KR#612/2,421 Sec#19/57 |
| Total Debt | 10.00B KRW | KR#1,624/2,421 Sec#37/57 |
| FCF | -3.24B KRW | KR#1,404/2,421 Sec#39/57 |
| Cash | 7.61B KRW | KR#1,839/2,421 Sec#40/57 |
| Current Ratio | 2.50x | KR#689/2,421 Sec#18/57 |
| Performance | ||
| 1Y Return | -32.71% | KR#1,640/2,421 Sec#34/57 |
| 1M Return | 1.13% | KR#1,100/2,421 Sec#23/57 |
| From 52W High | -38.84% | KR#875/2,421 Sec#25/57 |
| 1Y MDD | -48.90% | KR#943/2,421 Sec#31/57 |
| Trading | ||
| Volume | 3,868 shares | KR#2,181/2,421 Sec#51/57 |
| Trading Value | 10.8M KRW | KR#2,266/2,421 Sec#52/57 |
| Foreign Own. | 0.78% | KR#2,120/2,421 Sec#47/57 |
| Per Share | ||
| EPS | 226 KRW | KR#1,255/2,421 Sec#32/57 |
| BPS | 5,982 KRW | KR#1,361/2,421 Sec#28/57 |
Company Info
Bifido, established in 1999 and listed on KOSDAQ in 2018, manufactures Bifidobacterium-based probiotics discovered in Korean infant intestines. It operates its own brand, Bifidolab, and provides domestic and international ODM services, possessing a proprietary patented strain, the sixth in the world to receive NDI and GRAS certifications from the US FDA. Through the development of MAP-based functional probiotics and eLBP microbiome therapeutics, Bifido is building a competitive pipeline targeting immune, cancer, and infectious diseases.